IP Library Granted Patent US 12,377,081
Granted Patent B2
US 12,377,081 · App. 18/484,564 · Granted Aug 5, 2025

Liquid nimodipine compositions

Inventor: Hugh Greg Thomas (Carrollton, GA)
Assignee: AZURITY PHARMACEUTICALS, INC.
A61K31/4422A61K9/08A61K47/10A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,081
App. No.
18/484,564
Granted
Aug 5, 2025
Kind
B2
Abstract

Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.

Claims (15)

1. A liquid composition comprising nimodipine and a solvent system from about 50% to about 97% (w/v) polyethylene glycol (PEG), from about 1% to about 15% (w/v) water, from about 0.5% to about 5% (w/v) ethanol, and optionally from about 1% to about 50% (w/v) glycerin, wherein the concentration of nimodipine is about 6 mg/mL, and wherein about 10% or less nimodipine degradation is observed over a period of at least three months when exposed to 25° C. and 60% relative humidity.

2. The liquid composition of claim 1 , wherein nimodipine is present in an amount from about 10 mg to about 100 mg per dosage unit.

3. The liquid composition of claim 2 , wherein nimodipine is present in an amount of about 60 mg per dosage unit.

4. The liquid composition of claim 2 , wherein nimodipine is present in an amount of about 30 mg per dosage unit.

5. The liquid composition of claim 1 , further comprising one or more preservatives.

6. The liquid composition of claim 5 , wherein the one or more preservatives is a paraben preservative.

7. The liquid composition of claim 6 , wherein the paraben preservative is methylparaben, propylparaben, ethylparaben, butylparaben, isobutylparaben, isopropylparaben, benzylparaben, or any combination thereof.

8. The liquid composition of claim 1 , wherein the polyethylene glycol is PEG 300, PEG 400, or a mixture thereof.

9. The liquid composition of claim 1 , wherein the solvent system comprises about 50% to about 75% (w/v) polyethylene glycol.

10. The liquid composition of claim 1 , wherein the solvent system comprises about 65% to about 97% (w/v) polyethylene glycol.

11. The liquid composition of claim 1 , wherein the solvent system comprises about 0.5% to about 1% (w/v) ethanol.

12. The liquid composition of claim 1 , wherein the solvent system comprises about 1% to about 5% (w/v) ethanol.

13. The liquid composition of claim 1 , wherein the solvent system comprises from about 40% to about 50% (w/v) glycerin.

14. The liquid composition of claim 1 , wherein about 10% or less nimodipine degradation is observed over a period of at least six months when exposed to 25° C. and 60% relative humidity.

15. The liquid composition of claim 1 , wherein about 10% or less nimodipine degradation is observed over a period of at least three months when exposed to 40° C. and 75% relative humidity.

Assignments (3)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2024
From: THOMAS, HUGH GREG
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 066612/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2024
From: ARBOR PHARMACEUTICALS, LLC
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 066612/0541 →